Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program with WEvenamide as Add-On Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
